<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002031</url>
  </required_header>
  <id_info>
    <org_study_id>047A</org_study_id>
    <nct_id>NCT00002031</nct_id>
  </id_info>
  <brief_title>Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)</brief_title>
  <official_title>Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number,&#xD;
      morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related&#xD;
      complex (ARC) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinitrochlorobenzene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Stage III or IV HIV infection.&#xD;
&#xD;
          -  Provide informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Kaposi's sarcoma lesions in the proposed treatment sites.&#xD;
&#xD;
          -  Liable to require radiation or chemotherapy during the course of the study.&#xD;
&#xD;
          -  Not likely to survive the length of the study.&#xD;
&#xD;
          -  Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with&#xD;
             recent UV exposure or likely to have such exposure (e.g.:&#xD;
&#xD;
          -  holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to&#xD;
             lidocaine.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other Immunomodulators.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Kaposi's sarcoma lesions in the proposed treatment sites.&#xD;
&#xD;
          -  Liable to require radiation or chemotherapy during the course of the study.&#xD;
&#xD;
          -  Not likely to survive the length of the study.&#xD;
&#xD;
          -  Obvious ultra-violet-irradiated skin damage in the treatment areas.&#xD;
&#xD;
          -  Allergy to lidocaine.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior DNCB therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991 Aug;29(3):191-6. doi: 10.1016/0165-2478(91)90169-b. Erratum In: Immunol Lett 1992 Aug;33(3):316.</citation>
    <PMID>1769706</PMID>
  </reference>
  <verification_date>February 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Langerhans Cells</keyword>
  <keyword>Dinitrochlorobenzene</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

